Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Sho Iketania Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA;b Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA

Lihong Liua Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Manoj S. Naira Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

https://orcid.org/0000-0002-5994-3957

Abishek Chandrashekarc Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Hiroshi Mohria Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Maple Wanga Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Dan H. Barouchc Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;d Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA;e Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA

Yaoxing Huanga Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

David D. Hoa Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA;b Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA;f Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USACorrespondence[email protected]

show all

References

Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021 Jul 31;398(10298):385–387.
PubMed Web of Science ®Google Scholar
Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 May;593(7857):130–135.
PubMed Web of Science ®Google Scholar
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021 Aug;596(7871):276–280.
PubMed Web of Science ®Google Scholar
Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021 Jun 10;384(23):2212–2218.
PubMed Web of Science ®Google Scholar
Brinkley-Rubinstein L, Peterson M, Martin R, et al. Breakthrough SARS-CoV-2 infections in prison after vaccination. N Engl J Med. 2021 Sep 9;385(11):1051–1052.
Web of Science ®Google Scholar
Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021 May 12;29(5):747–751 e4.
PubMed Web of Science ®Google Scholar
Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021 Sep 11;398(10304):981–990.
PubMed Web of Science ®Google Scholar

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date